<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250305111903
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250305111903" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 05 Mar 2025 16:19:05 +0000</lastbuilddate>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40038847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 5:ehaf001. doi: 10.1093/eurheartj/ehaf001. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40038847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40038847</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf001>10.1093/eurheartj/ehaf001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40038847</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexandra Butters</dc:creator>
<dc:creator>Kate Thomson</dc:creator>
<dc:creator>Franki Harrington</dc:creator>
<dc:creator>Natasha Henden</dc:creator>
<dc:creator>Karen McGuire</dc:creator>
<dc:creator>Alicia B Byrne</dc:creator>
<dc:creator>Samantha Bryen</dc:creator>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Megan Leask</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>John Atherton</dc:creator>
<dc:creator>Johan M Bos</dc:creator>
<dc:creator>Colleen Caleshu</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Kyla Dunn</dc:creator>
<dc:creator>Ian Hayes</dc:creator>
<dc:creator>Jimmy Juang</dc:creator>
<dc:creator>Julie McGaughran</dc:creator>
<dc:creator>Natalie Nowak</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Anne Ronan</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Jil C Tardiff</dc:creator>
<dc:creator>Marianne Tiemensma</dc:creator>
<dc:creator>Tony R Merriman</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Jonathan R Skinner</dc:creator>
<dc:creator>Daniel G MacArthur</dc:creator>
<dc:creator>Owen M Siggs</dc:creator>
<dc:creator>Richard D Bagnall</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets</dc:title>
<dc:identifier>pmid:40038847</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf001</dc:identifier>
</item>
<item>
<title>Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehae931. doi: 10.1093/eurheartj/ehae931. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae931>10.1093/eurheartj/ehae931</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037651</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Dick C Chan</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies</dc:title>
<dc:identifier>pmid:40037651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae931</dc:identifier>
</item>
<item>
<title>Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093/eurheartj/ehae938. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037646</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae938>10.1093/eurheartj/ehae938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037646</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Andrew Coats</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Martina Brueckmann</dc:creator>
<dc:creator>Sibylle J Hauske</dc:creator>
<dc:creator>Elke Schueler</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial</dc:title>
<dc:identifier>pmid:40037646</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae938</dc:identifier>
</item>
<item>
<title>Gaining the upper hand on peripheral artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehaf132. doi: 10.1093/eurheartj/ehaf132. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037639</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf132>10.1093/eurheartj/ehaf132</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037639</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Francisco Ujueta</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Marie Gerhard-Herman</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gaining the upper hand on peripheral artery disease</dc:title>
<dc:identifier>pmid:40037639</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf132</dc:identifier>
</item>
<item>
<title>High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A high intensity exercise programme is feasible in patients with HCM, with apparent cardiovascular and psychological benefits, and no increase in arrhythmias. A large-scale study is required to substantiate findings and assess long-term safety of high intensity exercise in HCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3:ehae919. doi: 10.1093/eurheartj/ehae919. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The feasibility and impact of high intensity exercise programmes in patients with hypertrophic cardiomyopathy (HCM) are unknown. This study was conducted to determine the feasibility of a high intensity exercise programme and explore safety and efficacy outcomes in patients with HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants were randomized to a 12-week supervised exercise programme (n = 40) in addition to usual care, or usual care alone (n = 40). All participants underwent assessment at baseline and 12 weeks. The exercise group was re-evaluated 6 months post-programme. Feasibility was assessed by (i) recruitment, adherence, and retention rates; (ii) staffing ratios; (iii) logistics; and (iv) acceptability of the intervention. The primary exploratory safety outcome was a composite of arrhythmia-related events. Exploratory secondary outcomes included changes in (i) cardiorespiratory fitness; (ii) cardiovascular risk factors; and (iii) quality of life, anxiety, and depression scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 67 (84%) participants completed the study (n = 34 and n = 33 in the exercise and usual care groups, respectively). Reasons for non-adherence included travel, work, and family commitments. Resource provision complied with national cardiac rehabilitation standards. There was no difference between groups for the exploratory safety outcome (P = .99). At 12 weeks, the exercise group had a greater increase in peak oxygen consumption (VO2) [+4.1 mL/kg/min, 95% confidence interval (CI) 1.1, 7.1] and VO2 at anaerobic threshold (+2.3 mL/kg/min, 95% CI 0.4, 4.1), lower systolic blood pressure (-7.3 mmHg, 95% CI -11.7, -2.8) and body mass index (-0.8 kg/m2, 95% CI -1.1, -0.4), and greater improvement in hospital anxiety (-3, 95% CI -4.3, -1.7) and depression (-1.7, 95% CI -2.9, -0.5) scores, compared to the usual care group. Most exercise gains dissipated at 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A high intensity exercise programme is feasible in patients with HCM, with apparent cardiovascular and psychological benefits, and no increase in arrhythmias. A large-scale study is required to substantiate findings and assess long-term safety of high intensity exercise in HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037382</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae919>10.1093/eurheartj/ehae919</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037382</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Joyee Basu</dc:creator>
<dc:creator>Dimitra Nikoletou</dc:creator>
<dc:creator>Chris Miles</dc:creator>
<dc:creator>Hamish MacLachlan</dc:creator>
<dc:creator>Gemma Parry-Williams</dc:creator>
<dc:creator>Fred Tilby-Jones</dc:creator>
<dc:creator>Paulo Bulleros</dc:creator>
<dc:creator>Zephryn Fanton</dc:creator>
<dc:creator>Claire Baker</dc:creator>
<dc:creator>Shane Purcell</dc:creator>
<dc:creator>Carmen Lech</dc:creator>
<dc:creator>Tracy Chapman</dc:creator>
<dc:creator>Peter Sage</dc:creator>
<dc:creator>Shams Wahid</dc:creator>
<dc:creator>Nabeel Sheikh</dc:creator>
<dc:creator>Shruti Jayakumar</dc:creator>
<dc:creator>Aneil Malhotra</dc:creator>
<dc:creator>Tracey Keteepe-Arachi</dc:creator>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Gherardo Finocchiaro</dc:creator>
<dc:creator>Gerald Carr-White</dc:creator>
<dc:creator>Elijah Behr</dc:creator>
<dc:creator>Maite Tome</dc:creator>
<dc:creator>Jamie O'Driscoll</dc:creator>
<dc:creator>Irina Chis Ster</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial</dc:title>
<dc:identifier>pmid:40037382</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae919</dc:identifier>
</item>
<item>
<title>Targeted approach for next-generation coronary stents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3:ehaf007. doi: 10.1093/eurheartj/ehaf007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037368</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf007>10.1093/eurheartj/ehaf007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037368</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Simon D Brown</dc:creator>
<dc:creator>Julie Rodor</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Targeted approach for next-generation coronary stents</dc:title>
<dc:identifier>pmid:40037368</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf007</dc:identifier>
</item>
<item>
<title>Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>Bacterial immunotherapy holds promising cancer-fighting potential. However, unlocking its power requires a mechanistic understanding of how bacteria both evade antimicrobial immune defenses and stimulate anti-tumor immune responses within the tumor microenvironment (TME). Here, by harnessing an engineered Salmonella enterica strain with this dual proficiency, we unveil an underlying singular mechanism. Specifically, the hysteretic nonlinearity of interleukin-10 receptor (IL-10R) expression...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20:S0092-8674(25)00158-8. doi: 10.1016/j.cell.2025.02.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bacterial immunotherapy holds promising cancer-fighting potential. However, unlocking its power requires a mechanistic understanding of how bacteria both evade antimicrobial immune defenses and stimulate anti-tumor immune responses within the tumor microenvironment (TME). Here, by harnessing an engineered Salmonella enterica strain with this dual proficiency, we unveil an underlying singular mechanism. Specifically, the hysteretic nonlinearity of interleukin-10 receptor (IL-10R) expression drives tumor-infiltrated immune cells into a tumor-specific IL-10R<sup>hi</sup> state. Bacteria leverage this to enhance tumor-associated macrophages producing IL-10, evade phagocytosis by tumor-associated neutrophils, and coincidently expand and stimulate the preexisting exhausted tumor-resident CD8<sup>+</sup> T cells. This effective combination eliminates tumors, prevents recurrence, and inhibits metastasis across multiple tumor types. Analysis of human samples suggests that the IL-10R<sup>hi</sup> state might be a ubiquitous trait across human tumor types. Our study unveils the unsolved mechanism behind bacterial immunotherapy's dual challenge in solid tumors and provides a framework for intratumoral immunomodulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037354</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.002>10.1016/j.cell.2025.02.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037354</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Zhiguang Chang</dc:creator>
<dc:creator>Xuan Guo</dc:creator>
<dc:creator>Xuefei Li</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Zhongsheng Zang</dc:creator>
<dc:creator>Siyu Pei</dc:creator>
<dc:creator>Weiqi Lu</dc:creator>
<dc:creator>Yang Li</dc:creator>
<dc:creator>Jian-Dong Huang</dc:creator>
<dc:creator>Yichuan Xiao</dc:creator>
<dc:creator>Chenli Liu</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization</dc:title>
<dc:identifier>pmid:40037354</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.002</dc:identifier>
</item>
<item>
<title>Non-traditional risk factors and artificial intelligence in the management of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3;46(9):771-774. doi: 10.1093/eurheartj/ehaf028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037331</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf028>10.1093/eurheartj/ehaf028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037331</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-traditional risk factors and artificial intelligence in the management of atrial fibrillation</dc:title>
<dc:identifier>pmid:40037331</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf028</dc:identifier>
</item>
<item>
<title>Exercise prescription in hypertrophic cardiomyopathy: Dr Lown's lesson to break taboos</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3:ehae659. doi: 10.1093/eurheartj/ehae659. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40037289</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae659>10.1093/eurheartj/ehae659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037289</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Flavio D'Ascenzi</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise prescription in hypertrophic cardiomyopathy: Dr Lown's lesson to break taboos</dc:title>
<dc:identifier>pmid:40037289</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae659</dc:identifier>
</item>
<item>
<title>Mixed valvular heart disease: diagnosis and management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036874/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>Mixed valvular diseases (MVDs) are common but have received little attention in the literature, especially regarding the mitral valve (MV) and the right-sided cardiac valves. Whereas echocardiography plays a pivotal diagnostic role, the diagnosis is made difficult due to haemodynamic interactions that may invalidate common indices of severity used in isolated stenosis or regurgitation. The diagnostic strategy should aim at initially separately assessing stenosis and regurgitation, taking into...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 27:ehaf116. doi: 10.1093/eurheartj/ehaf116. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mixed valvular diseases (MVDs) are common but have received little attention in the literature, especially regarding the mitral valve (MV) and the right-sided cardiac valves. Whereas echocardiography plays a pivotal diagnostic role, the diagnosis is made difficult due to haemodynamic interactions that may invalidate common indices of severity used in isolated stenosis or regurgitation. The diagnostic strategy should aim at initially separately assessing stenosis and regurgitation, taking into account the diagnostic pitfalls, with complementary use of multimodality imaging in cases of persisting diagnostic uncertainties. Unlike aortic stenosis, the calcium score cannot be used as a surrogate for haemodynamic severity of mixed MV disease. Severe stenosis and/or severe regurgitation are indicative of severe MVD, and management should follow recommendations on the predominant lesion. However, some patients with the combination of moderate stenosis and moderate regurgitation have a poor prognosis when left untreated. Concordant data suggest that, in patients with mixed aortic or MV disease, transvalvular velocities and pressure gradients are more powerful prognostic indicators than valve area or the severity of regurgitation. It is essential to consider the global repercussions that indicate poor outcomes in patients with MVD. However, whereas symptoms and/or ventricular dysfunction are considered as clear indication for intervention, imaging cut-offs have not been validated for balanced moderate regurgitation and stenosis. Although emerging evidence tends to support earlier management, further prospective studies are required, and pending the results of these studies, asymptomatic patients with MVD should be closely monitored.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036874/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036874</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf116>10.1093/eurheartj/ehaf116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036874</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Philippe Unger</dc:creator>
<dc:creator>Xavier Galloo</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mixed valvular heart disease: diagnosis and management</dc:title>
<dc:identifier>pmid:40036874</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf116</dc:identifier>
</item>
<item>
<title>Extracellular vesicles to mediate RNA therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036797/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf046. doi: 10.1093/eurheartj/ehaf046. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036797/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036797</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf046>10.1093/eurheartj/ehaf046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036797</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Jes-Niels Boeckel</dc:creator>
<dc:creator>Junjie Xiao</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Extracellular vesicles to mediate RNA therapies</dc:title>
<dc:identifier>pmid:40036797</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf046</dc:identifier>
</item>
<item>
<title>Drug-coated balloons in small vessel de novo coronary artery disease: better than DES?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036794/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf083. doi: 10.1093/eurheartj/ehaf083. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036794/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036794</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf083>10.1093/eurheartj/ehaf083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036794</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Christina Lalani</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Drug-coated balloons in small vessel de novo coronary artery disease: better than DES?</dc:title>
<dc:identifier>pmid:40036794</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf083</dc:identifier>
</item>
<item>
<title>Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>The aim of this whitepaper is to review the current state of the literature on the effects of cardio-oncology rehabilitation and exercise (CORE) programmes and provide a roadmap for improving the evidence-based to support the implementation of CORE. There is an urgent need to reinforce and extend the evidence informing the cardiovascular care of cancer survivors. CORE is an attractive model that is potentially scalable to improve the cardiovascular health of cancer survivors as it leverages many...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf100. doi: 10.1093/eurheartj/ehaf100. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The aim of this whitepaper is to review the current state of the literature on the effects of cardio-oncology rehabilitation and exercise (CORE) programmes and provide a roadmap for improving the evidence-based to support the implementation of CORE. There is an urgent need to reinforce and extend the evidence informing the cardiovascular care of cancer survivors. CORE is an attractive model that is potentially scalable to improve the cardiovascular health of cancer survivors as it leverages many of the existing frameworks developed through decades of delivery of cardiac rehabilitation. However, there are several challenges within this burgeoning field, including limited evidence of the efficacy of this approach in patients with cancer. In this paper, a multidisciplinary team of international experts highlights priorities for future research in this field and recommends standards for the conduct of research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036781/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036781</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf100>10.1093/eurheartj/ehaf100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036781</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Scott C Adams</dc:creator>
<dc:creator>Fernando Rivera-Theurel</dc:creator>
<dc:creator>Jessica M Scott</dc:creator>
<dc:creator>Michelle B Nadler</dc:creator>
<dc:creator>Stephen Foulkes</dc:creator>
<dc:creator>Darryl Leong</dc:creator>
<dc:creator>Tormod Nilsen</dc:creator>
<dc:creator>Charles Porter</dc:creator>
<dc:creator>Mark Haykowsky</dc:creator>
<dc:creator>Husam Abdel-Qadir</dc:creator>
<dc:creator>Sarah C Hull</dc:creator>
<dc:creator>Neil M Iyengar</dc:creator>
<dc:creator>Christina M Dieli-Conwright</dc:creator>
<dc:creator>Susan F Dent</dc:creator>
<dc:creator>Erin J Howden</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group</dc:title>
<dc:identifier>pmid:40036781</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf100</dc:identifier>
</item>
<item>
<title>Loss of the Y chromosome in coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf072. doi: 10.1093/eurheartj/ehaf072. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf072>10.1093/eurheartj/ehaf072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036778</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Soichi Sano</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loss of the Y chromosome in coronary artery disease</dc:title>
<dc:identifier>pmid:40036778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf072</dc:identifier>
</item>
<item>
<title>The SWEDEGRAFT trial: when absence of evidence is not evidence of absence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036740/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf043. doi: 10.1093/eurheartj/ehaf043. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036740/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036740</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf043>10.1093/eurheartj/ehaf043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036740</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The SWEDEGRAFT trial: when absence of evidence is not evidence of absence</dc:title>
<dc:identifier>pmid:40036740</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf043</dc:identifier>
</item>
<item>
<title>Opportunities and challenges in preventing heart failure: when is risk modifiable?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036736/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf042. doi: 10.1093/eurheartj/ehaf042. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036736/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036736</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf042>10.1093/eurheartj/ehaf042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036736</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Felix Lindberg</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Opportunities and challenges in preventing heart failure: when is risk modifiable?</dc:title>
<dc:identifier>pmid:40036736</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf042</dc:identifier>
</item>
<item>
<title>European Society of Cardiology guidelines for the management of valvular heart disease: should we apply these to rheumatic heart disease?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036734/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehae641. doi: 10.1093/eurheartj/ehae641. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036734/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036734</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae641>10.1093/eurheartj/ehae641</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036734</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Ana Mocumbi</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Society of Cardiology guidelines for the management of valvular heart disease: should we apply these to rheumatic heart disease?</dc:title>
<dc:identifier>pmid:40036734</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae641</dc:identifier>
</item>
<item>
<title>Renal artery stenosis from dislodged occluder</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 27:ehaf093. doi: 10.1093/eurheartj/ehaf093. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036592</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf093>10.1093/eurheartj/ehaf093</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036592</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Quan Yang</dc:creator>
<dc:creator>Run Wang</dc:creator>
<dc:creator>Mingya Liu</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Renal artery stenosis from dislodged occluder</dc:title>
<dc:identifier>pmid:40036592</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf093</dc:identifier>
</item>
<item>
<title>The Year in Cardiovascular Medicine 2024: the top 10 papers in valvular heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036584/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 27:ehaf071. doi: 10.1093/eurheartj/ehaf071. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036584/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036584</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf071>10.1093/eurheartj/ehaf071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036584</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Helmut Baumgartner</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Year in Cardiovascular Medicine 2024: the top 10 papers in valvular heart disease</dc:title>
<dc:identifier>pmid:40036584</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf071</dc:identifier>
</item>
<item>
<title>Unilateral pulmonary oedema</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 27:ehaf095. doi: 10.1093/eurheartj/ehaf095. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036581</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf095>10.1093/eurheartj/ehaf095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036581</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>William Griffin</dc:creator>
<dc:creator>Charles McCreery</dc:creator>
<dc:creator>Alessandro N Franciosi</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Unilateral pulmonary oedema</dc:title>
<dc:identifier>pmid:40036581</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf095</dc:identifier>
</item>
<item>
<title>Distinct inflammatory pathways shape atherosclerosis in different vascular beds</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305111903&amp;v=2.18.0.post9+e462414
      <description>Studies suggest varying atherosclerotic cardiovascular disease (ASCVD) prevalence across arterial beds. Factors such as smoking expedite ASCVD progression in the abdominal aorta, while diabetes accelerates plaque development in lower limb arteries, and hypertension plays a significant role in ASCVD development in the coronary and carotid arteries. Moreover, superficial femoral atherosclerosis advances slower compared with atherosclerosis in coronary and carotid arteries. Furthermore, femoral...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 27:ehaf054. doi: 10.1093/eurheartj/ehaf054. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Studies suggest varying atherosclerotic cardiovascular disease (ASCVD) prevalence across arterial beds. Factors such as smoking expedite ASCVD progression in the abdominal aorta, while diabetes accelerates plaque development in lower limb arteries, and hypertension plays a significant role in ASCVD development in the coronary and carotid arteries. Moreover, superficial femoral atherosclerosis advances slower compared with atherosclerosis in coronary and carotid arteries. Furthermore, femoral atherosclerosis exhibits higher levels of ossification and calcification, but lower cholesterol concentrations compared with atherosclerotic lesions of other vascular beds. Such disparities exemplify the diverse progression of ASCVD across arterial beds, pointing towards differential mechanistic pathways in each vascular bed. Hence, this review summarizes current literature on immune-inflammatory mechanisms in various arterial beds in ASCVD to advance our understanding of this disease in an aging society with increased need of vascular bed and patient-specific treatment options.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305111903&v=2.18.0.post9+e462414">40036569</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf054>10.1093/eurheartj/ehaf054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036569</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Oliver Soehnlein</dc:creator>
<dc:creator>Esther Lutgens</dc:creator>
<dc:creator>Yvonne Döring</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Distinct inflammatory pathways shape atherosclerosis in different vascular beds</dc:title>
<dc:identifier>pmid:40036569</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf054</dc:identifier>
</item>





























</channel>
</rss>